Risk-stratified prostate cancer screening
Risk-stratified prostate cancer screening has been studied in 2 papers since 2026: 1 observational study in people, 1 review; 2 in the past year. The newest paper, Oct 21, 2026: “Risk-stratified Prostate Cancer Screening in 2026: Blood- and Urine-based Biomarkers”.
2 papers study it2 findingsUpdated
2 new papers in 30 daysSee all 2
- Humans1
What did studies of Risk-stratified prostate cancer screening find?
2Studies of Risk-stratified prostate cancer screening measured 2 outcomes; the most studied are prostate cancer overdiagnosis (1 study) and early detection of clinically significant prostate cancer (1).
Prostate cancer overdiagnosis
downin humans1
1 study
Prostate cancer overdiagnosis
downin humans1
Risk-stratified prostate cancer screening decreases prostate cancer overdiagnosis in humans.
“risk-stratified, imaging- and biomarker-driven approaches offer pragmatic and evidence-based pathways to enhance early detection of csPCa while reducing overdiagnosis and overtreatment.”
Reviewmales
Risk-stratified Prostate Cancer Screening in 2026: Blood- and Urine-based Biomarkers
European urology focus
Early detection of clinically significant prostate cancer
upin humans1
1 study
Early detection of clinically significant prostate cancer
upin humans1
Risk-stratified prostate cancer screening improves early detection of clinically significant prostate cancer in humans.
“risk-stratified, imaging- and biomarker-driven approaches offer pragmatic and evidence-based pathways to enhance early detection of csPCa while reducing overdiagnosis and overtreatment.”
Reviewmales
Risk-stratified Prostate Cancer Screening in 2026: Blood- and Urine-based Biomarkers
European urology focus